A GSK-led con­sor­tium looks to break ground with a new class of an­tibi­ot­ic, push­ing in­to a piv­otal

Af­ter watch­ing a slew of biotechs crash and burn af­ter field­ing a line­up of fresh­ly ap­proved an­tibi­otics, Glax­o­SmithK­line is hop­ing to achieve some­thing new in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER